NCT07205042

Brief Summary

Women with hypothyroidism often report persistent fatigue, weight gain, autonomic dysregulation, and stress despite stable levothyroxine therapy. This single-center, parallel-group RCT will test whether a structured, supervised 12-week walking program improves basal metabolic rate (BMR) and psychophysiological outcomes compared with usual activity. One hundred twenty women aged 35-55 with stable primary hypothyroidism will be randomized 1:1 to intervention or control.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
2mo left

Started Nov 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress78%
Nov 2025Jun 2026

First Submitted

Initial submission to the registry

September 13, 2025

Completed
20 days until next milestone

First Posted

Study publicly available on registry

October 3, 2025

Completed
29 days until next milestone

Study Start

First participant enrolled

November 1, 2025

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Expected
Last Updated

October 3, 2025

Status Verified

September 1, 2025

Enrollment Period

6 months

First QC Date

September 13, 2025

Last Update Submit

September 30, 2025

Conditions

Keywords

WalkingAerobic ExerciseBasal Metabolic RateHeart Rate VariabilitySalivary Cortisol

Outcome Measures

Primary Outcomes (1)

  • Change in Basal Metabolic Rate

    Baseline (Week 0) and Week 12

    Basal metabolic rate (BMR) measured via indirect calorimetry under standardized conditions (fasted, thermoneutral room, supine rest ≥30 minutes). The primary analysis will compare change from baseline to 12 weeks between intervention and control groups.

Secondary Outcomes (5)

  • Change in Heart Rate Variability

    Baseline (Week 0) and Week 12

  • Change in Heart Rate Variability

    Baseline (Week 0) and Week 12

  • Change in Morning Salivary Cortisol

    Baseline (Week 0) and Week 12

  • Change in Fatigue Severity Scale

    Baseline (Week 0) and Week 12

  • Change in Hospital Anxiety and Depression Scale

    Baseline (Week 0) and Week 12

Other Outcomes (2)

  • Adherence to Walking Program

    Weekly throughout the 12-week intervention period

  • Adverse Events

    From Week 1 through Week 12 (study intervention period)

Study Arms (2)

Walking Intervention

EXPERIMENTAL

Participants will undergo a supervised walking program consisting of 30 minutes per session, 5 sessions per week, for 12 weeks. Exercise intensity will be maintained at 55-65% of age-predicted maximum heart rate, monitored by chest strap or optical heart rate sensors. Sessions will be supervised by an exercise physiologist, with adherence tracked through session logs and heart rate recordings. Participants will continue their usual levothyroxine regimen but will not initiate any new structured exercise program during the study period.

Behavioral: Supervised Walking Program

Control (Usual Activity)

NO INTERVENTION

Participants will continue their usual daily routines without a prescribed exercise program. They will be instructed not to initiate any new structured exercise during the study. Weekly check-ins will be conducted to record incidental activity and monitor health status. At study completion, control participants will be offered the walking program.

Interventions

A structured walking program consisting of 30 minutes per session, 5 sessions per week, for 12 weeks at 55-65% of age-predicted maximum heart rate. Sessions will be supervised by an exercise physiologist, with adherence monitored by heart rate tracking and attendance logs. Participants will continue their standard levothyroxine treatment but will not begin any new structured exercise programs.

Also known as: Aerobic walking, treadmill walking, moderate-intensity exercise
Walking Intervention

Eligibility Criteria

Age35 Years - 55 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Female, aged 35-55 years
  • Primary hypothyroidism with documented prior TSH \>4.5 mIU/L
  • Stable levothyroxine dose for at least 6 months
  • Sedentary lifestyle (\<150 minutes of moderate-vigorous activity per week)
  • BMI between 20-35 kg/m²
  • Able to walk unaided
  • Willing and able to provide written informed consent

You may not qualify if:

  • Pregnant or lactating, or planning pregnancy during the study period
  • Use of beta-blockers, systemic corticosteroids, or medications significantly affecting heart rate, HRV, or metabolism
  • Uncontrolled hypertension, insulin-dependent diabetes, symptomatic cardiovascular disease, or orthopedic conditions limiting walking
  • Major psychiatric hospitalization in the past 12 months
  • Participation in another interventional trial within the past 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Karachi

Karachi, Sindh, 78500, Pakistan

Location

Related Publications (4)

  • Sundus H, Khan SA, Zaidi S, Chhabra C, Ahmad I, Khan H. Effect of long-term exercise-based interventions on thyroid function in hypothyroidism: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2025 Sep;92:103196. doi: 10.1016/j.ctim.2025.103196. Epub 2025 May 28.

    PMID: 40446861BACKGROUND
  • Dunabeitia I, Gonzalez-Devesa D, Varela-Martinez S, Diz-Gomez JC, Ayan-Perez C. Effect of physical exercise in people with hypothyroidism: systematic review and meta-analysis. Scand J Clin Lab Invest. 2023 Dec;83(8):523-532. doi: 10.1080/00365513.2023.2286651. Epub 2024 Jan 24.

    PMID: 37999992BACKGROUND
  • Mathene Koteles E, Rafael B, Korom A, Vagvolgyi A, Abraham JE, Domjan A, Szucs M, Nemes A, Barnai M, Lengyel C, Kosa I. Physiological and psychological effects of a 12-week home-based telemonitored training in metabolic syndrome. Front Cardiovasc Med. 2023 Jan 10;9:1075361. doi: 10.3389/fcvm.2022.1075361. eCollection 2022.

    PMID: 36704473BACKGROUND
  • Ahmad AM, Serry ZH, Abd Elghaffar HA, Ghazi HA, El Gayar SL. Effects of aerobic, resistance, and combined training on thyroid function and quality of life in hypothyroidism. A randomized controlled trial. Complement Ther Clin Pract. 2023 Nov;53:101795. doi: 10.1016/j.ctcp.2023.101795. Epub 2023 Aug 22.

    PMID: 37659172BACKGROUND

MeSH Terms

Conditions

Hypothyroidism

Condition Hierarchy (Ancestors)

Thyroid DiseasesEndocrine System Diseases

Study Officials

  • Sadaf Ahmed, Ph.D.

    University of Karachi

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Shamoon Noushad, Ph.D.

CONTACT

Sadaf Ahmed, Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The walking program cannot be blinded to participants or exercise staff. However, outcome assessors (BMR testing, HRV analysis, cortisol assays) and statisticians will be blinded to group allocation.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Participants will be randomized 1:1 into two arms: (1) a 12-week supervised walking program and (2) a control group maintaining usual activity. Each group is followed in parallel for the full duration of the study.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 13, 2025

First Posted

October 3, 2025

Study Start

November 1, 2025

Primary Completion

April 30, 2026

Study Completion (Estimated)

June 30, 2026

Last Updated

October 3, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

The individual participant data (IPD) collected during this study will not be made publicly available due to ethical and privacy considerations. Summary results will be disseminated in scientific publications and presentations.

Locations